A communication from the Executive Office of Health and Human Services (see Section 80 of Chapter 118E of the General Laws) submitting its report on the needs of MassHealth enrollees with a diagnosis of sickle cell disease and the adequacy of available covered medications, treatments and health care services

This bill is a communication from the Executive Office of Health and Human Services that submits a report on the healthcare needs of MassHealth enrollees diagnosed with sickle cell disease. The report evaluates the adequacy of currently covered medications, treatments, and health services for this patient population. It includes data on hospitalizations and emergency room visits between July 2022 and June 2024, as well as a list of specific drugs such as hydroxyurea, voxelotor, and gene therapies. The document was placed on file in August 2026.